Preclinical study discovered that when administrated at pico- to nanomolar concentrations, HDP-101 exhibited profound cytotoxicity to BCMA+ myeloma cell lines and non-proliferating primary MM cells isolated from patients with R/R MM irrespective of BCMA expression level [90, 91]. Here, TNFRSF17 is linked to Miyoshi myopathy.